Delivering Unprecedented Access to Biosimilars in Global Markets
  • Building a focused, sustainable and profitable
    biosimilar business
  • Improving patient access to important, cost-effective
    medicines worldwide
  • Advancing our products through strategic partnerships
    to maximize future value
Who We Are

EPIRUS is a global biopharmaceutical company focused on building a sustainable and profitable rare disease biosimilar business by improving patient access through cost-effective medicines.  Our ability to deliver on this vision is anchored in our strong technical platform and pragmatic approach to development and commercialization.

Learn More


May 9, 2016

EPIRUS Announces Reprioritization of Pipeline to Solely Focus on Biosimilars to Treat Rare Diseases and Key Leadership Changes

March 15, 2016

EPIRUS Biopharmaceuticals Reports Fourth Quarter and Fiscal Year 2015 Financial Results and Provides Business Update



February 12, 2016

EPIRUS Biopharmaceuticals to Participate in Bloomberg Intelligence Healthcare Event on February 12

February 10, 2016

EPIRUS Biopharmaceuticals to Present at LEERINK Partners 5th Annual Global Healthcare Conference


Bookmark and Share